**** The editor has said, “Please correct the mismatches found between the labeling of supplementary figures and the legends.” It is unclear what mismatches there are below... please clarify.

Appendix

Figure S1

A) PD-L1 expression on BrCa cell lines. Representative plot from MDA MB 468.

B) Quantification of CD4+ /CD8+ splenocytes from the in vivo EMT6 study. Representative plot shown.

Figure S1. Representative flow cytometry gating strategies
A) PD-L1 expression on BrCa cell lines. Representative plot from MDA MB 468.
B) Quantification of CD4+/CD8+ splenocytes from the in vivo EMT6 study. Representative plot shown.
Figure S2

A)

Figure S2. Representative diagram of the in vivo experimental protocol

A) Four groups of 12-week old BALB/c mice (Charles River) were implanted on day 0 with $2 \times 10^5$ EMT6 cells subcutaneously (s.c) into the right mammary pad (N=15/group). Once tumors were palpable (approximately day 6), therapy was initiated. Mice were grouped into cohorts and treated with i.p PBS, intratumoral live RV ($5 \times 10^8$ PFU), anti-PD-1 antibody (RMP1-14, BioXcell, Connecticut, USA ) (0.2 mg i.p.), or a combination of these agents.
Figure S3. Representative flow cytometry gating strategies

A) Quantification of memory CD4/CD8 T cells (TEM, TCM) from the in vivo EMT6 study. Representative plot shown.

B) Quantification of Treg (CD4+CD25+FOXP3+) from in vivo EMT6 study. Representative plot shown.
Figure S4. Representative flow cytometry gating strategies

A) Quantification of intracellular cytokine production from CD4+/CD8+ splenocytes from the in vivo EMT6 study. Representative plot of IFNγ shown.